CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 15 enrolled
Drug / intervention
ALXN1850biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04980248
NCT04980248Phase 1Completed
CompareCT.gov

A Phase 1, Open-label, Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ALXN1850 in Adults With Hypophosphatasia

Alexion Pharmaceuticals, Inc.·interventional·Posted Jul 28, 2021·Updated Dec 27, 2024

In Brief

A Phase 1 clinical trial evaluating ALXN1850 for Hypophosphatasia. Completed, enrolled 15 participants across 4 sites.

Detailed Summary

This is an open-label, dose-escalating study to assess safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and immunogenicity of ALXN1850 when given intravenous (IV) and subcutaneous (SC) to adults with HPP.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypophosphatasia
CountriesUnited States
Collaborators--

Timeline

Phase 1CompletedFinished
20222023202420252026
First PostedJul 28, 2021
Enrollment StartSep 28, 2021
Primary CompletionAug 24, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.9 years ago

Interventions

ALXN1850biological

ALXN1850 will be administered as an IV infusion and via the SC route.